Midatech Pharma Plcの発行済株式数
Midatech Pharma Plcの発行済株式数は何ですか。
Midatech Pharma Plcの発行済株式数は63.381Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
LSEのセクタHealth Careにおける発行済株式数の企業と比べるMidatech Pharma Plc
Midatech Pharma Plcは何をしますか。
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Midatech Pharma Plcと類似の発行済株式数
- Streamline Health Solutions, Incの発行済株式数は63.324Mです。
- SKRR Explorationの発行済株式数は63.326Mです。
- Blueprint Medicines Corpの発行済株式数は63.345Mです。
- Photronicsの発行済株式数は63.357Mです。
- Cineplexの発行済株式数は63.363Mです。
- Provention Bioの発行済株式数は63.375Mです。
- Midatech Pharma Plcの発行済株式数は63.381Mです。
- Mayfield Childcareの発行済株式数は63.409Mです。
- Nubian Resourcesの発行済株式数は63.410Mです。
- Shree Rama Multi-Techの発行済株式数は63.468Mです。
- Shree Rama Multi-Techの発行済株式数は63.468Mです。
- Adcoreの発行済株式数は63.471Mです。
- Apollo Investmentの発行済株式数は63.519Mです。